Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy

Key Points

• KRAS mutations significantly influence treatment outcomes in nonsquamous non-small cell lung cancer (NSCLC).
• Patients with specific co-alterations alongside KRAS mutations show varied responses to chemoradiation combined with immunotherapy.
• Assessment used clinical data from numerous patient cases undergoing treatment for stage III nonsquamous NSCLC.
• Highlights the need for individualized treatment approaches based on genetic makeup in lung cancer cases.